Invivyd (IVVD) Net Income towards Common Stockholders Growth (1y) (2022 - 2026)
Powered by 
Analysis
Invivyd (IVVD) Net Income towards Common Stockholders Growth (1y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 65.85% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -635.24% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 6.48% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -6.81% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 92.37% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.21% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 327.74% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -84.64% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 95.87% |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | -204.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -204.25% |
| Dec 31, 2025 | 34.71% |
| Sep 30, 2025 | 82.31% |
| Jun 30, 2025 | 69.42% |
| Mar 31, 2025 | 63.28% |
| Dec 31, 2024 | 74.95% |
| Sep 30, 2024 | -44.71% |
| Jun 30, 2024 | 8.59% |
| Mar 31, 2024 | -17.96% |
| Dec 31, 2023 | -59.20% |
| Sep 30, 2023 | 9.02% |
| Jun 30, 2023 | -4.11% |
| Mar 31, 2023 | 61.22% |
| Dec 31, 2022 | 41.98% |
| Sep 30, 2022 | 21.60% |
| Jun 30, 2022 | -15.84% |
| Mar 31, 2022 | -160.25% |